Revenue segments as reported by the company.

Pharmaceutical

Animal Health

Other Revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Research and development

Restructuring costs

Other (income) expense, net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Merck

Merck & Co., Inc. engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Kenilworth, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Merck reports robust Q4 earnings, eyes growth through innovation

Merck's Q4 2022 performance reflects strong revenue growth and strategic advancements across key therapeutic areas, positioning the company for future success.
While facing challenges such as patent estate concerns and competitive pressures, Merck's focus on innovation and partnerships presents opportunities for sustained growth.
Analyst inquiries and executive responses during the earnings call highlight the company's commitment to transparency, patient outcomes, and shareholder value.

Merck reports robust Q1 earnings, eyes growth in oncology and vaccines

Merck's Q1 performance reflects strong revenue growth driven by oncology and vaccines, with a raised full-year guidance and focus on pipeline advancements.
The company's strategic strengths lie in its focus on compelling science, value alignment in business decisions, and commitment to innovation.
Challenges include potential impacts of EU legislation, post-KEYTRUDA LOE growth strategies, and navigating regulatory complexities for new treatments.
Opportunities in expansion in China, revenue diversification, innovative combination therapies, and protective treatment strategies position Merck for future growth.

Merck reports robust Q2 earnings, focuses on growth opportunities

Merck's Q2 performance showcased strong earnings driven by Oncology and Vaccines growth
Despite challenges like regulatory concerns and price pressures, the company remains focused on innovation
Opportunities lie in expanding KEYTRUDA's reach in cancer indications and advancing in immunology
Overall, Merck's strategic acquisitions and commitment to growth position it well for the future

Merck reports robust Q3 earnings, eyes growth in precision medicine

Merck's Q3 2023 Earnings Call highlighted strong revenue growth, pipeline advancements, and increased full-year revenue guidance. The company's strategic focus on key therapeutic areas and precision medicine approaches positions it for continued success and innovation.

Merck reports robust Q4 earnings, eyes growth through strategic investments

Merck's strong Q4 performance was driven by KEYTRUDA and Vaccines, with positive revenue guidance for 2024. The company remains focused on R&D advancements, strategic investments, and shareholder value. Challenges include managing expenses and maximizing market opportunities.

Merck reports robust Q1 earnings, eyes growth in innovative treatments

Merck's Q1 performance reflects strong revenue growth, operational efficiency, and a positive outlook for future earnings.
The company's focus on innovation, strategic investments, and commitment to patient access position it well for long-term success.
Challenges in pipeline differentiation and market competition require continued strategic planning and differentiation strategies.
Opportunities in new treatment areas, market expansion, and upcoming events offer avenues for sustained growth and market leadership.

Merck reports robust Q2 earnings, eyes future drug launches

Merck's Q2 earnings call highlighted strong financial performance, innovative product launches, and confidence in future growth. The company addressed analyst inquiries, emphasizing long-term pipeline growth and short-term financial guidance while expressing gratitude for investor support.

Merck reports solid Q3 earnings, eyes growth through diversification

Merck's Q3 2024 performance reflects revenue growth driven by key products and clinical advancements, despite regional sales variations and inventory challenges.
The company's strengths in diversification, clinical progress, and strategic investments position it well for future growth and competitive edge in the market.
While facing challenges in specific product sales and clinical trials, Merck has opportunities to capitalize on its strengths, expand offerings, and drive sustained growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

Avient Corp

Best Buy

Franklin Resources

Eversource Energy

Exelon

Hasbro

Hormel Foods

Interpublic Group of Companies

Kraft Heinz

Mondelez

NextEra Energy

Omnicom Group

Prudential Financial

Regions Financial

Stanley Black & Decker

Calvert Research and Management's annual review identified the top 100 sustainable companies based on over 230 ESG performance indicators, including workplace diversity and greenhouse-gas emissions. Eight dividend-paying sustainable companies offer annual dividends from a $1K investment exceeding their single share prices, signaling potential buy opportunities. Analysts forecast net gains of 27.62% to 59.85% for top ESG companies by January 2026, with Regions Financial leading at an estimated 59.84%.

3 Ideal Buys From 51 'Safer' Dividends In 100 January Barron's Sustainable Dogs

PALO ALTO, Calif.--(BUSINESS WIRE)--Atropos Health, a pioneer in translating real-world clinical data into real-world evidence (RWE) for decision-making, today announced it will collaborate with Merck as a premier platform to generate RWE, replicate studies and produce rapid insights and analytics on real-world data (RWD). Through this collaboration, Atropos Health will enable rapid cohort creation, advanced analytics and publication-grade studies in less than 48 hours. As part of the agreement.

Atropos Health Collaborates with Merck for Rapid Evidence Generation to Accelerate Innovation for Life-Saving Treatments

Amgen

BridgeBio Pharma Inc

Bristol-Myers

Iovance Biotherapeutics

Eli Lilly

Madrigal Pharmaceuticals

Pfizer

Zevra Therapeutics Inc

The FDA wrapped up 2024 with 50 new drug approvals, clearing a wave of long-awaited treatments. Meanwhile, Transcarent will take Accolade private.

Healthy Returns: The FDA approved fewer new drugs in 2024 — but some big ones hit the market

Moderna

UBS lowered its price targets for Pfizer, Merck, and Moderna stocks.

There's a ‘Shadow' Over Biotech Stocks. Why It Isn‘t All Bad News.

KeyCorp

Seagate Technology Holdings PLC

Looking for some truly wowing profit growth from S&P 500 companies. A few are likely to knock your socks off.

8 Stocks' Huge Profit Growth Is About To Knock Your Socks Off

Merck & Co. Inc. (NYSE: MRK) is rewarding its shareholders once again with a quarterly dividend of $0.81 per share, payable on Wednesday, Jan.

Merck Just Paid Investors: How Much Did They Receive?

RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck's GARDASIL® Receives Expanded Approval for Males in China.

Merck's GARDASIL® Receives Expanded Approval for Males in China

U.S. drugmaker Merck & Co said on Wednesday its human papillomavirus (HPV) vaccine for men has been approved by China's medical products administration.

Merck says its HPV vaccine for men was approved by China's drug regulator

Wuxi Biologics Cayman Inc

WuXi Biologics' move to sell the facility could strengthen the company's cash flow and margins as it navigates global uncertainties.

WuXi Biologics to Sell Irish Vaccine Facility to Merck for $500 Million

Merck (MRK) closed at $99.72 in the latest trading session, marking a +0.59% move from the prior day.

Merck (MRK) Rises Higher Than Market: Key Facts

China's WuXi Biologics said on Monday it will sell its vaccine facility in Ireland to Merck for about $500 million.

China's WuXi Biologics to sell Ireland vaccine facility to Merck for $500 million

RAHWAY, N.J.--(BUSINESS WIRE)--Merck to Participate in the 43rd Annual J.P. Morgan Healthcare Conference.

Merck to Participate in the 43rd Annual J.P. Morgan Healthcare Conference

Cisco Systems

Chevron

Johnson & Johnson

Coca-Cola

McDonald's

Procter & Gamble

Verizon

The Dogs of the Dow 2025 pay big dividends—up to 6.8%! Collectively they yield three-times what the broader market pays.

Big Blue Chip Dividends? Try These ‘Dogs' Up To 6.8%

Boeing

Salesforce

Disney

Goldman Sachs

Home Depot

JPMorgan Chase & Co

Microsoft

NVIDIA

UnitedHealth Group

Verizon Communications is the only Dow Dog meeting the ideal of annual dividends from $1K invested, exceeding the single share price. Analysts forecast 11.36% to 31.73% net gains from the top ten Dow Dogs by January 2026, with Merck leading at $313.37. A market correction of 82% could make all top ‘safer' Dow dividend dogs fair-priced, with dividends from $1K invested meeting or exceeding share prices.

January Dow Dogs: 1 'Safer' Buy, And 5 With Promise

Recently, Zacks.com users have been paying close attention to Merck (MRK). This makes it worthwhile to examine what the stock has in store.

Merck & Co., Inc. (MRK) Is a Trending Stock: Facts to Know Before Betting on It

The ‘Dogs of the Dow' is a well-known strategy first published in 1991 by Michael Higgins.

2025's Five Highest Yielding Dogs of the Dow Could Explode Higher

UK's Medicines and Healthcare products Regulatory Agency (MHRA) said on Tuesday it had approved Merck's therapy to treat a rare lung condition called pulmonary arterial hypertension.

UK approves Merck's therapy for rare lung condition

The healthcare sector has long been a sanctuary for income investors seeking stability and growth. Within this realm, Bristol-Myers Squibb (BMY -2.81%) and Merck & Co. (MRK -1.33%) stand out for their combination of above-average dividend yields and proven business models.

2 High-Yield Dividend Stocks to Buy Early in 2025

The latest trading day saw Merck (MRK) settling at $98.37, representing a -1.33% change from its previous close.

Merck (MRK) Sees a More Significant Dip Than Broader Market: Some Facts to Know

Kimberly-Clark

PepsiCo

Large-capitalization dividend stocks are a favorite among investors for a good reason.

US Large Cap Dividend Stocks Should Roll in 2025: Our 4 Favorite Picks

There is plenty to like about Merck (MRK -0.25%). It is one of the largest pharmaceutical companies and the owner of the world's current best-selling drug, cancer medicine Keytruda.

2 Reasons to Sell Merck Stock and 1 Reason to Buy

Amazon

Caterpillar

Sherwin-Williams

The year 2024 saw the U.S. stock market make new records, with major indices breaching key milestones. While many stocks witnessed a stellar rally this year, analysts still expect some blue-chip equities to rise further as they forecast a better return potential.

Top 7 Blue-Chip Stocks With The Best Return Potential Going Into 2025

Merck (MRK) closed the most recent trading day at $99.45, moving +0.08% from the previous trading session.

Merck (MRK) Rises Yet Lags Behind Market: Some Facts Worth Knowing

Merck will discontinue its drug for a bacterial infection that can lead to fatal diarrhea, the U.S. Food and Drug Administration's website showed on Monday.

Merck to discontinue drug for bacterial infection

News for Merck Stock (MRK)